Immunic Appoints Highly Experienced Neurology Expert Michael Panzara as Chief Medical Officer

summarizeSummary

Immunic, Inc. appointed Dr. Michael A. Panzara, a seasoned neurology expert, as its new Chief Medical Officer, replacing co-founder Dr. Andreas Muehler, who will transition to a consulting role.

check_boxKey Events

• New Chief Medical Officer Appointed

  Dr. Michael A. Panzara, a biopharmaceutical executive with over 25 years of neurology drug development experience, including significant work on multiple sclerosis therapies at Sanofi Genzyme and Biogen, was appointed CMO, effective April 24, 2026.

• Strategic Alignment with Lead Program

  Dr. Panzara's expertise is highly relevant as Immunic progresses its lead program, vidofludimus calcium, through pivotal Phase 3 clinical trials for relapsing multiple sclerosis.

• Significant Equity Incentive Granted

  Dr. Panzara received an initial equity option to purchase 300,000 shares of common stock under the Immunic, Inc. 2026 Inducement Equity Compensation Plan, granted as an inducement material to his employment.

• Outgoing CMO Transitions to Consulting Role

  Dr. Andreas Muehler, a co-founder and the previous Chief Medical Officer, resigned on April 27, 2026, but will continue to support the company as a consultant for an initial period of ten months, receiving severance benefits including a lump sum payment and full vesting of outstanding equity awards.

auto_awesomeAnalysis

Immunic, a late-stage biotechnology company, has appointed Dr. Michael A. Panzara as its new Chief Medical Officer, effective April 24, 2026. Dr. Panzara brings over 25 years of global neurology experience, including leadership roles at Sanofi Genzyme and Biogen where he oversaw regulatory approvals for multiple sclerosis drugs. This appointment is strategically significant as Immunic advances its lead program, vidofludimus calcium, through pivotal Phase 3 trials for relapsing MS. The outgoing CMO, Dr. Andreas Muehler, a co-founder, has resigned but will transition to a consulting role, ensuring continuity. Dr. Panzara's substantial equity option grant (300,000 shares, representing over 2% of the company's market cap) aligns his incentives with long-term shareholder value. This leadership change positions the company with strong clinical development expertise as it approaches key milestones, following the recent 1-for-10 reverse stock split.